INVO Bioscience has signed a definitive merger agreement for the acquisition of 100% of the outstanding equity shares of NAYA Biosciences to establish a publicly traded life science company.

The takeover will be carried out through a reverse triangular merger of INVO’s fully-owned subsidiary with and into NAYA. 

The combined business will run as INVO’s wholly-owned subsidiary under the name NAYA Biosciences.

The combined company will focus on boosting access of patients to life-transforming therapies in the fields of oncology, fertility and regenerative medicine. 

NAYA shareholders will receive 7.3333 INVO shares for each share held.

The boards of directors of the companies have granted unanimous approval for the merger, set to conclude in Q4 2023, subject to approval from the stockholders of INVO, Cytovia and NAYA.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Current NAYA Biosciences chairman and CEO Dr Daniel Teper will serve as chairman and CEO of the new combined entity.

INVO Bioscience chairman and CEO Steve Shum stated: “We are excited by the opportunity to merge INVO and NAYA with the financial resources to advance both the fertility and newly acquired oncology operations. 

“We believe this combination provides the benefit of having existing revenue-generating operations from our fertility business and an ability to further grow those activities, along with the upside potential of innovative cancer therapeutics.”